123 related articles for article (PubMed ID: 30623801)
1. Immune cell derived BDNF does not mediate neuroprotection of the murine anti-CD52 antibody in a chronic autoimmune mouse model.
Demir S; Pitarokoili K; Linker R; Gold R
J Neuroimmunol; 2019 Mar; 328():78-85. PubMed ID: 30623801
[TBL] [Abstract][Full Text] [Related]
2. Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase.
Hao W; Luo Q; Menger MD; Fassbender K; Liu Y
Front Immunol; 2021; 12():792465. PubMed ID: 34975892
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels.
Barbour M; Wood R; Hridi SU; Wilson C; McKay G; Bushell TJ; Jiang HR
J Neuroimmunol; 2018 May; 318():87-96. PubMed ID: 29526407
[TBL] [Abstract][Full Text] [Related]
4. Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: therapeutic implications in a model of multiple sclerosis.
Linker RA; Lee DH; Demir S; Wiese S; Kruse N; Siglienti I; Gerhardt E; Neumann H; Sendtner M; Lühder F; Gold R
Brain; 2010 Aug; 133(Pt 8):2248-63. PubMed ID: 20826430
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD52 antibody treatment depletes B cell aggregates in the central nervous system in a mouse model of multiple sclerosis.
Simon M; Ipek R; Homola GA; Rovituso DM; Schampel A; Kleinschnitz C; Kuerten S
J Neuroinflammation; 2018 Aug; 15(1):225. PubMed ID: 30098594
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD52 blocks EAE independent of PD-1 signals and promotes repopulation dominated by double-negative T cells and newly generated T and B cells.
Haile Y; Adegoke A; Laribi B; Lin J; Anderson CC
Eur J Immunol; 2020 Sep; 50(9):1362-1373. PubMed ID: 32388861
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD52 antibody treatment in murine experimental autoimmune encephalomyelitis induces dynamic and differential modulation of innate immune cells in peripheral immune and central nervous systems.
Barbour M; Wood R; Harte T; Bushell TJ; Jiang HR
Immunology; 2022 Mar; 165(3):312-327. PubMed ID: 34826154
[TBL] [Abstract][Full Text] [Related]
8. Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
von Kutzleben S; Pryce G; Giovannoni G; Baker D
Immunology; 2017 Apr; 150(4):444-455. PubMed ID: 27925187
[TBL] [Abstract][Full Text] [Related]
9. Targeting CD52 does not affect murine neuron and microglia function.
Ellwardt E; Vogelaar CF; Maldet C; Schmaul S; Bittner S; Luchtman D
Eur J Pharmacol; 2020 Mar; 871():172923. PubMed ID: 31962100
[TBL] [Abstract][Full Text] [Related]
10. Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis.
Turner MJ; Pang PT; Chretien N; Havari E; LaMorte MJ; Oliver J; Pande N; Masterjohn E; Carter K; Reczek D; Brondyk W; Roberts BL; Kaplan JM; Siders WM
J Neuroimmunol; 2015 Aug; 285():4-12. PubMed ID: 26198912
[TBL] [Abstract][Full Text] [Related]
11. Brain-derived neurotrophic factor and TrkB receptor in experimental autoimmune encephalomyelitis and multiple sclerosis.
De Santi L; Annunziata P; Sessa E; Bramanti P
J Neurol Sci; 2009 Dec; 287(1-2):17-26. PubMed ID: 19758606
[TBL] [Abstract][Full Text] [Related]
12. Brain-derived neurotrophic factor precursor in the immune system is a novel target for treating multiple sclerosis.
Hu ZL; Luo C; Hurtado PR; Li H; Wang S; Hu B; Xu JM; Liu Y; Feng SQ; Hurtado-Perez E; Chen K; Zhou XF; Li CQ; Dai RP
Theranostics; 2021; 11(2):715-730. PubMed ID: 33391501
[No Abstract] [Full Text] [Related]
13. Involvement of brain-derived neurotrophic factor (BDNF) in MP4-induced autoimmune encephalomyelitis.
Javeri S; Rodi M; Tary-Lehmann M; Lehmann PV; Addicks K; Kuerten S
Clin Immunol; 2010 Nov; 137(2):181-9. PubMed ID: 20797911
[TBL] [Abstract][Full Text] [Related]
14. Treatment with a recombinant human IgM that recognizes PSA-NCAM preserves brain pathology in MOG-induced experimental autoimmune encephalomyelitis.
Lemus HN; Warrington AE; Denic A; Wootla B; Rodriguez M
Hum Antibodies; 2017; 25(3-4):121-129. PubMed ID: 28269761
[TBL] [Abstract][Full Text] [Related]
15. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
Thöne J; Ellrichmann G; Seubert S; Peruga I; Lee DH; Conrad R; Hayardeny L; Comi G; Wiese S; Linker RA; Gold R
Am J Pathol; 2012 Jan; 180(1):267-74. PubMed ID: 22152994
[TBL] [Abstract][Full Text] [Related]
16. Ulinastatin attenuates experimental autoimmune encephalomyelitis by enhancing anti-inflammatory responses.
Feng M; Shu Y; Yang Y; Zheng X; Li R; Wang Y; Dai Y; Qiu W; Lu Z; Hu X
Neurochem Int; 2014 Jan; 64():64-72. PubMed ID: 24274996
[TBL] [Abstract][Full Text] [Related]
17. Alteration of CD39+Foxp3+ CD4 T cell and cytokine levels in EAE/MS following anti-CD52 treatment.
Pant AB; Wang Y; Mielcarz DW; Kasper EJ; Telesford KM; Mishra M; Haque A; Channon JY; Kasper LH; Begum-Haque S
J Neuroimmunol; 2017 Feb; 303():22-30. PubMed ID: 28087077
[TBL] [Abstract][Full Text] [Related]
18. CNS delivery of anti-CD52 antibodies modestly reduces disease severity in an animal model for multiple sclerosis.
Bogie JF; Grajchen E; Wouters E; Broux B; Stinissen P; Van Wijmeersch B; Hendriks JJ
Ther Adv Chronic Dis; 2020; 11():2040622320947378. PubMed ID: 32913622
[TBL] [Abstract][Full Text] [Related]
19. Connexin 30 Deficiency Attenuates Chronic but Not Acute Phases of Experimental Autoimmune Encephalomyelitis Through Induction of Neuroprotective Microglia.
Fang M; Yamasaki R; Li G; Masaki K; Yamaguchi H; Fujita A; Isobe N; Kira JI
Front Immunol; 2018; 9():2588. PubMed ID: 30464764
[TBL] [Abstract][Full Text] [Related]
20. 2'-5' oligoadenylate synthetase-like 1 (OASL1) deficiency suppresses central nervous system damage in a murine MOG-induced multiple sclerosis model.
Choi BY; Sim CK; Cho YS; Sohn M; Kim YJ; Lee MS; Suh SW
Neurosci Lett; 2016 Aug; 628():78-84. PubMed ID: 27297771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
